Quick Answer
Sunshine Biopharma Inc. reported Total Revenue of $34.87 million for fiscal year 2024.
Sunshine Biopharma Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $34.87M +44.7% |
$24.09M +454.4% |
$4.35M +1802.4% |
$228.4K +219.9% |
$71.4K +238.1% |
$21.1K |
| Net Income | -$5.13M -13.9% |
-$4.51M +83.2% |
-$26.74M -115.0% |
-$12.44M -346.7% |
-$2.78M -67.7% |
-$1.66M +23.0% |
| Diluted EPS | -$7.32 +97.9% |
-$351.36 -19863.6% |
-$1.76 +63.0% |
-$4.76 | — | — |
| Total Assets | $30.56M +11.8% |
$27.35M -6.5% |
$29.24M +1227.5% |
$2.20M +110.7% |
$1.05M +965.3% |
$98.1K -91.4% |
| Cash and Equivalents | — | — | $21.83M +967.2% |
$2.05M +106.6% |
$989.9K +2344.1% |
$40.5K -63.4% |
| Stockholders Equity | $23.50M +10.8% |
$21.21M -1.9% |
$21.63M +10118.0% |
$211.7K +122.2% |
-$954.8K -29.8% |
-$735.4K -1219.0% |
| R&D Expense | $933.9K -49.7% |
$1.86M +128.6% |
$811.9K +20.8% |
$672.2K +38801.0% |
$1.7K -88.6% |
$15.2K +18.8% |
| Operating Income | -$5.81M -21.5% |
-$4.79M +82.3% |
-$27.00M -1006.5% |
-$2.44M -323.0% |
-$576.9K +10.1% |
-$641.6K +44.9% |
| Gross Profit | $10.67M +27.9% |
$8.34M +391.5% |
$1.70M +1434.0% |
$110.6K +142.7% |
$45.6K +352.4% |
$10.1K |
| Shares Outstanding | 2.58M +18313.5% |
14,012 -99.9% |
22.59M +771.6% |
2.59M +49.6% |
1.73M -95.1% |
35.32M +724.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $9.42M | +11.6% | +0.1% |
| Net Income | September 30, 2025 | -$883.8K | +26.2% | +50.1% |
| Diluted EPS | March 31, 2025 | -$0.44 | +78.0% | +78.0% |
| Total Assets | September 30, 2025 | $31.49M | +4.8% | -1.5% |
| Cash and Equivalents | June 30, 2023 | $19.73M | -52.7% | +2.3% |
| Long-Term Debt | June 30, 2021 | $2.05M | — | +116.5% |
| Stockholders Equity | September 30, 2025 | $24.20M | -3.4% | -5.8% |
| R&D Expense | September 30, 2025 | $119.3K | -5.6% | -39.2% |
| Operating Income | September 30, 2025 | -$1.09M | +1.8% | +47.1% |
| Gross Profit | September 30, 2025 | $3.07M | +7.2% | -10.2% |
| Shares Outstanding | September 30, 2025 | 4.56M | +127.8% | +0.0% |
- Sunshine Biopharma Inc. reported Total Revenue of $34.87 million for fiscal year 2024.
- Sunshine Biopharma Inc. showed an increase of +44.7% in Total Revenue compared to the prior fiscal year.
- Sunshine Biopharma Inc. reported Net Income of -$5.13 million for fiscal year 2024.
- Sunshine Biopharma Inc. showed a decrease of -13.9% in Net Income compared to the prior fiscal year.
- Sunshine Biopharma Inc. reported Diluted EPS of $7.32 per share (loss) for fiscal year 2024.
- Sunshine Biopharma Inc. showed an increase of +97.9% in Diluted EPS compared to the prior fiscal year.
- Sunshine Biopharma Inc. reported Total Assets of $30.56 million for fiscal year 2024.
- Sunshine Biopharma Inc. showed an increase of +11.8% in Total Assets compared to the prior fiscal year.
- Sunshine Biopharma Inc. reported Cash and Equivalents of $21.83 million for fiscal year 2022.
- Sunshine Biopharma Inc. showed an increase of +967.2% in Cash and Equivalents compared to the prior fiscal year.
- Sunshine Biopharma Inc. reported Stockholders Equity of $23.50 million for fiscal year 2024.
- Sunshine Biopharma Inc. showed an increase of +10.8% in Stockholders Equity compared to the prior fiscal year.
- Sunshine Biopharma Inc. reported R&D Expense of $933.9 thousand for fiscal year 2024.
- Sunshine Biopharma Inc. showed a decrease of -49.7% in R&D Expense compared to the prior fiscal year.
- Sunshine Biopharma Inc. reported Operating Income of -$5.81 million for fiscal year 2024.
- Sunshine Biopharma Inc. showed a decrease of -21.5% in Operating Income compared to the prior fiscal year.
- Sunshine Biopharma Inc. reported Gross Profit of $10.67 million for fiscal year 2024.
- Sunshine Biopharma Inc. showed an increase of +27.9% in Gross Profit compared to the prior fiscal year.
- Sunshine Biopharma Inc. reported Shares Outstanding of 2.58 million shares for fiscal year 2024.
- Sunshine Biopharma Inc. showed an increase of +18313.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: